Exelixis Future Growth

Future criteria checks 2/6

Exelixis is forecast to grow earnings and revenue by 15.8% and 9.1% per annum respectively. EPS is expected to grow by 17.1% per annum. Return on equity is forecast to be 18.7% in 3 years.

Key information

15.8%

Earnings growth rate

17.1%

EPS growth rate

Biotechs earnings growth27.6%
Revenue growth rate9.1%
Future return on equity18.7%
Analyst coverage

Good

Last updated19 Dec 2024

Recent future growth updates

Recent updates

Exelixis: Cabometyx Drives Revenue While Zanzalintinib Emerges As Future Growth Engine

Oct 31

Exelixis, Inc.'s (NASDAQ:EXEL) Shares Leap 25% Yet They're Still Not Telling The Full Story

Oct 31
Exelixis, Inc.'s (NASDAQ:EXEL) Shares Leap 25% Yet They're Still Not Telling The Full Story

Here's Why We Think Exelixis (NASDAQ:EXEL) Is Well Worth Watching

Oct 26
Here's Why We Think Exelixis (NASDAQ:EXEL) Is Well Worth Watching

Getting In Cheap On Exelixis, Inc. (NASDAQ:EXEL) Might Be Difficult

Sep 02
Getting In Cheap On Exelixis, Inc. (NASDAQ:EXEL) Might Be Difficult

Exelixis Comes Up Aces

Aug 08

If EPS Growth Is Important To You, Exelixis (NASDAQ:EXEL) Presents An Opportunity

Jun 14
If EPS Growth Is Important To You, Exelixis (NASDAQ:EXEL) Presents An Opportunity

It's Unlikely That Exelixis, Inc.'s (NASDAQ:EXEL) CEO Will See A Huge Pay Rise This Year

May 24
It's Unlikely That Exelixis, Inc.'s (NASDAQ:EXEL) CEO Will See A Huge Pay Rise This Year

Exelixis' (NASDAQ:EXEL) Strong Earnings Are Of Good Quality

May 07
Exelixis' (NASDAQ:EXEL) Strong Earnings Are Of Good Quality

Exelixis: With Patent Litigation Decision Due Soon, There Are Options

May 02

Exelixis, Inc.'s (NASDAQ:EXEL) Earnings Haven't Escaped The Attention Of Investors

Apr 22
Exelixis, Inc.'s (NASDAQ:EXEL) Earnings Haven't Escaped The Attention Of Investors

Exelixis: Patent Woes And Challenging Market Dynamics Make For A Testy 2024

Mar 28

We Ran A Stock Scan For Earnings Growth And Exelixis (NASDAQ:EXEL) Passed With Ease

Feb 26
We Ran A Stock Scan For Earnings Growth And Exelixis (NASDAQ:EXEL) Passed With Ease

Exelixis: Bullish Despite The High Stakes Game Of Cabometyx Patent Battles

Jan 17

Exelixis, Inc.'s (NASDAQ:EXEL) Revenues Are Not Doing Enough For Some Investors

Dec 27
Exelixis, Inc.'s (NASDAQ:EXEL) Revenues Are Not Doing Enough For Some Investors

Earnings and Revenue Growth Forecasts

NasdaqGS:EXEL - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/20262,44862856393714
12/31/20252,19549449366820
12/31/20242,16250935345118
9/30/20242,082467405470N/A
6/30/20242,014350166316N/A
3/31/20241,847205185318N/A
12/31/20231,830208170333N/A
9/30/20231,77492134396N/A
6/30/20231,714164213389N/A
3/31/20231,664154118299N/A
12/31/20221,611182224363N/A
9/30/20221,638308343385N/A
6/30/20221,555273310359N/A
3/31/20221,521298453509N/A
12/31/20211,435231337401N/A
9/30/20211,254164275338N/A
6/30/20211,15794218272N/A
3/31/20211,03165152192N/A
12/31/2020988112179209N/A
9/30/2020958152310334N/A
6/30/2020998282372391N/A
3/31/2020979294408421N/A
12/31/2019968321514527N/A
9/30/2019956612465474N/A
6/30/2019910642541563N/A
3/31/2019856650473506N/A
12/31/2018854690382416N/A
9/30/2018745368316364N/A
6/30/2018672323N/A237N/A
3/31/2018585253N/A169N/A
12/31/2017452154N/A166N/A
9/30/2017410150N/A197N/A
6/30/201732058N/A154N/A
3/31/20172576N/A122N/A
12/31/2016191-70N/A210N/A
9/30/2016124-147N/A90N/A
6/30/201671-181N/A61N/A
3/31/201643-186N/A60N/A
12/31/201537-162N/A-141N/A
9/30/201535-178N/A-156N/A
6/30/201531-195N/A-180N/A
3/31/201530-229N/A-208N/A
12/31/201425-261N/A-235N/A
9/30/201422-281N/A-233N/A
6/30/201421-286N/A-232N/A
3/31/201427-275N/A-216N/A
12/31/201331-245N/A-199N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: EXEL's forecast earnings growth (15.8% per year) is above the savings rate (2.6%).

Earnings vs Market: EXEL's earnings (15.8% per year) are forecast to grow faster than the US market (15.2% per year).

High Growth Earnings: EXEL's earnings are forecast to grow, but not significantly.

Revenue vs Market: EXEL's revenue (9.1% per year) is forecast to grow slower than the US market (9.1% per year).

High Growth Revenue: EXEL's revenue (9.1% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: EXEL's Return on Equity is forecast to be low in 3 years time (18.7%).


Discover growth companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/22 07:59
End of Day Share Price 2024/12/20 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Exelixis, Inc. is covered by 39 analysts. 20 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Ishan MajumdarBaptista Research
Peter LawsonBarclays
George FarmerBMO Capital Markets Equity Research